Stealth BioTherapeutics (NASDAQ:MITO) Releases Quarterly Earnings Results

Stealth BioTherapeutics (NASDAQ:MITO) released its quarterly earnings results on Monday. The company reported ($0.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by ($0.04), MarketWatch Earnings reports.

MITO stock opened at $1.50 on Wednesday. The firm has a market cap of $83.15 million, a price-to-earnings ratio of 37.51 and a beta of 2.25. The firm has a 50-day simple moving average of $1.74 and a two-hundred day simple moving average of $1.54. Stealth BioTherapeutics has a one year low of $1.19 and a one year high of $2.58.

About Stealth BioTherapeutics

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Further Reading: Understanding the different types of bonds

Earnings History for Stealth BioTherapeutics (NASDAQ:MITO)

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with's FREE daily email newsletter.